MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial) — MIMO

Acute Pulmonary Edema Clinical Trial

Official title:
Study Design and Rationale of "A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing MIdazolam Versus MOrphine in Acute Pulmonary Edema": MIMO Trial

Status Terminated

Clinical Trial Summary

Acute pulmonary edema (APE) is a common condition in the emergency room, associated with considerable mortality. The use of intravenous morphine in the treatment of APE remains controversial and Benzodiazepines have been suggested as an alternative for morphine to relieving dyspnoea and anxiety in the patients with APE. The MIdazolan versus MOrphine in APE trial (MIMO) is a multicenter, prospective, open-label, randomized study designed to evaluate the efficacy and safety of morphine in patients with APE.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02856698
Study type	Interventional
Source	Hospital Universitario de Canarias
Contact
Status	Terminated
Phase	Phase 4
Start date	April 8, 2017
Completion date	December 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01455766` - Volumetric Monitoring in Major Lung Surgery	N/A
Active, not recruiting	`NCT02880358` - Epidemiology and Prognostic of the Acute Heart Failure	N/A
Completed	`NCT03596931` - Prior Statin Use and Risk of CHF, ALO and Malignant Arrhythmia in Indonesian Post-Acute Coronary Syndrome Patients
Completed	`NCT03607201` - Acute Coronary Syndrome in Diabetic Patients